Michael E Bowdish, Christina E Barkauskas, Jessica R Overbey, Robert L Gottlieb, Keren Osman, Abhijit Duggal, Mary E Marks, Jonathan Hupf, Eustace Fernandes, Bradley G Leshnower, Jonathan L Golob, Alexander Iribarne, Athos J Rassias, Ellen G Moquete, Karen O'Sullivan, Helena L Chang, Judson B Williams, Sam Parnia, Nirav C Patel, Nimesh D Desai, Andrew M Vekstein, Beth A Hollister, Tammie Possemato, Christian Romero, Peter C Hou, Elizabeth Burke, Jack Hayes, Fred Grossman, Silviu Itescu, Marc Gillinov, Francis D Pagani, Patrick T O'Gara, Michael J Mack, Peter K Smith, Emilia Bagiella, Alan J Moskowitz, Annetine C Gelijns
RATIONALE: There are limited therapeutic options for patients with COVID-19-related acute respiratory distress syndrome (ARDS) with inflammation-mediated lung injury. Mesenchymal stromal cells offer promise as immunomodulatory agents. OBJECTIVES: Evaluation of efficacy and safety of allogeneic mesenchymal cells in mechanically-ventilated patients with moderate or severe COVID-induced respiratory failure. METHODS: Patients were randomized to two infusions of 2 million cells/kg or sham infusions, in addition to standard of care...
September 13, 2022: American Journal of Respiratory and Critical Care Medicine